OFA-I (oncofetal antigen-immunogenic) was first described in 1976 as a major tumor-associated antigen that was present on human cancer cells and fetal brain tissues. Although the amount of this antigen is consistently higher on tumors and fetal brain tissues, we later detected the antigen in adult brain and tissues of neural crest origin. OFA-I stimulates an appreciable immune response in man. We have developed two human monoclonal antibodies to OFA-I. These antibodies were produced by human B-lymphoblastoid cell lines (L55 and L72) immortalized by Epstein-Barr virus (EBV). Antibody produced by the L55 cell line reacts to an antigen (OFA-I-1) expressed on a variety of human cancer tissues. Antibody produced by the L72 cell line reacts to an antigen (OFA-I-2) on tumors of neuroectodermal origin. The chemical nature of OFA-I-1 was identified as the ganglioside GM2, and of OFA-I-2 as the ganglioside GD2. L72 has produced anti-GD2 antibody for the entire period of our observation (5 years), whereas antibody production by L55 eventually ceased during its long-term culture. The antibody production of both lines was relatively low, up to 5 to 10 micrograms of IgM/ml. Therefore, the projects set for the current research are: (1) augmentation of production of antibody from L72 and L55 cells by fusing these cells with human myeloma or lymphoid cells to form hybrids and by inoculating L55, L72, or the hybrid cells in immunologically suppressed animals; (2) establishment of new B-cell lines stable for the production of human monoclonal antibody to GM2 by EBV transformation techniques; (3) the production of a third human monoclonal antibody, antiganglioside GD3 antibody. GD3 is one of four gangliosides, GD2, GM2, GD3, and GM3, expressed by human melanomas, and our preliminary test has suggested that GD3 induces immune responses in man; and (4) the immunoglobulin class of the anti-GD2 and anti-GM2 are IgM. In the current research, we will investigate the feasibility of the production of human IgG monoclonal antibodies to GD2, GM2, and GD3. Production of both immunoglobulin classes to these melanoma-associated gangliosides should for the first time provide us with human monoclonal antibodies for immunodiagnosis and treatment of melanomas and other human cancer. (AG)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA030647-06
Application #
3169335
Study Section
Experimental Immunology Study Section (EI)
Project Start
1981-08-01
Project End
1988-05-31
Budget Start
1986-06-01
Budget End
1987-05-31
Support Year
6
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
Schools of Medicine
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Irie, Reiko F; Ollila, David W; O'Day, Steven et al. (2004) Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother 53:110-7
Takahashi, T; Johnson, T D; Nishinaka, Y et al. (1999) IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 112:205-9
Takahashi, T; Conforti, A; Kikumoto, Y et al. (1998) Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine. J Clin Immunol 18:299-305
Zhang, Z; Irie, R F; Chi, D D et al. (1998) Cellular immuno-PCR. Detection of a carbohydrate tumor marker. Am J Pathol 152:1427-32
Nishinaka, Y; Hoon, D S; Irie, R F (1998) Human IgM antibodies to tumor-associated gangliosides share VHIII (V3-23) and VKIV family subgroups. Immunogenetics 48:73-5
Takahashi, T; Irie, R F; Morton, D L et al. (1997) Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients. Cell Immunol 178:162-71
Nishinaka, Y; Ravindranath, M H; Irie, R F (1996) Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment. Cancer Res 56:5666-71
Kikumoto, Y; Oka, T; Cao, J N et al. (1995) Peptides with carboxyl-terminal sequence of alanine-proline: detection by a human monoclonal antibody. Hybridoma 14:45-50
Morioka, N; Kikumoto, Y; Hoon, D S et al. (1995) Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. Mol Immunol 32:573-81
Oka, T; Kikumoto, Y; Itakura, K et al. (1994) Human monoclonal antibody identified an immunoreactive tetrapeptide sequence (Lys-Tyr-Gln-Ile) in M(r) 43,000 protein of human melanoma. Cancer Res 54:3511-5

Showing the most recent 10 out of 26 publications